List of Vistogard drug patents

Vistogard is owned by Wellstat Therap.

Vistogard contains Uridine Triacetate.

Vistogard has a total of 2 drug patents out of which 0 drug patents have expired.

Vistogard was authorised for market use on 11 December, 2015.

Vistogard is available in granule;oral dosage forms.

Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.

The generics of Vistogard are possible to be released after 17 August, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6258795 WELLSTAT THERAP Acylated uridine and cytidine and uses thereof
Jul, 2023

(5 months from now)

US7776838 WELLSTAT THERAP Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Aug, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 11, 2022

Drugs and Companies using URIDINE TRIACETATE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours

Dosage: GRANULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in